Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · GKSL

GKSL

HealthcareHealthcare Services₹1199 cr market cap
₹150.50 ▼ -0.8% today As of 19 Nov 2026
52-week low ₹99.3652-week high ₹194.69

-22.1% from the 52-week high · +52.7% above the low

Gujarat Kidney & Super Speciality Ltd operates in the healthcare sector, specializing in nephrology and super-specialty medical services. The company manages healthcare facilities offering dialysis, kidney care, and related clinical services. Its operations focus on patient care, specialized medical infrastructure, and qualified professionals. The business model is service-oriented, generating revenue through treatments, procedures, and hospital services. Demand is driven by chronic care requirements and healthcare access needs.

The short version. GKSL reported revenue of ₹38 crore for Sep 2026, up 192.3% from a year earlier. Net profit was ₹6 crore (up 100.0% year on year). Return on equity was 6.1% in Mar 2026. Promoter holding was 71.45% in Sep 2026, up 0.00 points over 5 quarters.

1 · The price

How has the stock traded?

GKSL trades 22.1% below its 52-week high and 52.7% above its 52-week low.

Change over period: —

1M-19.2%
3M-3.5%
6M+8.1%
1Y—

2 · The business

Is it growing?

Sales, year on year+192.3%

Sep 2026 revenue of ₹38 cr.

Profit, year on year+100.0%

Sep 2026 net profit of ₹6 cr.

Net margin15.3%

5.3 pts lower than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025
Revenue3834312313
Net profit65533
Net margin %15.315.116.512.720.6
EPS (₹)0.740.660.640.370.34

Annual

FY2026
Revenue82
Net profit15
Net margin %18.9
EPS (₹)1.97

3 · The quality

How well does it turn capital into profit?

Return on equity was 6.1% in Mar 2026; debt to equity is 0.06.

Profitability · 1 years

Returns and margins

Mar 2026
Return on equity %6.1
Return on capital %8.6
EBITDA margin %33.6
Net margin %18.7

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.06
Interest cover12.3x
Current ratio3.76
P/E ratio26.8

4 · The owners

Who holds it, and are they adding?

Promoter holding71.45%

Unchanged over 5 quarters.

Foreign institutions6.53%

Down 6.56 pts over 5 quarters.

Domestic institutions0.26%

Down 7.58 pts over 5 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter71.4571.4571.4571.4571.450.0
FII13.0910.474.884.886.53-6.56
DII7.841.670.560.560.26-7.58
Public7.6216.423.123.121.77+14.15

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.02% of NAV
  • Bandhan BSE Healthcare Index Fund0.02% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for GKSL are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about GKSL

What is the GKSL share price?

GKSL (GKSL) last closed at ₹150.50, down 0.8% on the day. Its 52-week range is ₹99.36 to ₹194.69.

What is the market cap of GKSL?

GKSL has a market capitalisation of about ₹1,199 crore. Its price-to-earnings ratio is 26.8.

How are GKSL's latest results?

GKSL reported revenue of ₹38 crore for Sep 2026, up 192.3% from a year earlier. Net profit was ₹6 crore (up 100.0% year on year). Return on equity was 6.1% in Mar 2026. Promoter holding was 71.45% in Sep 2026, up 0.00 points over 5 quarters.

Who owns GKSL?

As of Sep 2026, shareholding was: Promoter 71.45%, FII 6.53%, DII 0.26%, Public 21.77%.

How many mutual funds hold GKSL?

2 mutual fund schemes held GKSL in October 2026. That compares with 2 the month before.

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.